Development and validation of fluorescent receptor assays based on the human recombinant estrogen receptor subtypes alpha and beta.

This article describes the development and validation of two fluorescent receptor assays for the hRec-estrogen receptor subtypes alpha and beta. As a labelled ligand an autofluorescent phyto-estrogen (coumestrol) has been used. The estrogen receptor (ER) belongs to the nuclear receptor family, a class of soluble DNA binding proteins, mainly present in the cytoplasm of the cell, that act as ligand-activated enhancer factors. It consists of two different forms, expressed as ER-alpha (66 kDa) and ER-beta (59 kDa). The ER-alpha is mainly located in the uterus and the ER-beta can be found in vascular tissue. Detection and identification of compounds having estrogenic effects is of importance in drug discovery programmes within the pharmaceutical industry for their search for ER-subtype selective (ant)agonists which may prove to be of therapeutic value in treating a variety of estrogen-linked pathologies (breast cancer, osteoporosis, cardiovascular disease, type II diabetes and Alzheimer disease). Furthermore, interactions of (xeno-)estrogens with the endogenous hormonal system of the exposed organism can affect embryos, gonads, and reproductive behaviour. The latter can eventually lead to reduced reproduction and deterioration of a population. For that reason, monitoring of (xeno-)estrogens in food products and in the environment, attracts considerable attention by health councils throughout the world. The following characteristics were obtained for the human recombinant (hRec) estrogen receptor-beta assay, which is suitable for ER subtype selective drug-discovery purposes (IC50 values for 17-beta-estradiol and genistein were 5.1 nM and 25 nM, respectively): goodness of fit (R2) was always > 0.98 (x = 0.9933, n = 10). LLOQ of the assay is typically > or = 500 picomolar, whereas the ULOQ of the assay is < or = 20.0 nanomolar. For the hRec-estrogen receptor-alpha assay, which is suitable for monitoring of (xeno-)estrogens (IC50 values for 17-beta-estradiol and genistein were 0.68 nM and 65 nM, respectively) the following characteristics were obtained: goodness of fit (R2) was always > 0.96 (x = 0.9838, n = 10). LLOQ of the assay is typically > or = 200 picomolar, whereas the ULOQ of the assay is < or = 5.0 nanomolar.

[1]  J. Gustafsson,et al.  ERβ a Novel Estrogen Receptor Offers the Potential for New Drug Development , 1998, Trends in Endocrinology & Metabolism.

[2]  F. E. Grubbs,et al.  Extension of Sample Sizes and Percentage Points for Significance Tests of Outlying Observations , 1972 .

[3]  J. Sumpter,et al.  Vitellogenesis as a biomarker for estrogenic contamination of the aquatic environment. , 1995, Environmental health perspectives.

[4]  R C Coombes,et al.  Estrogen receptor beta in breast cancer. , 2002, Endocrine-related cancer.

[5]  D L Massart,et al.  Validation of bioanalytical chromatographic methods. , 1998, Journal of pharmaceutical and biomedical analysis.

[6]  B. Katzenellenbogen,et al.  Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. , 2001, Journal of medicinal chemistry.

[7]  J. W. Findlay,et al.  Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. , 2000, Journal of pharmaceutical and biomedical analysis.

[8]  J. McGrath,et al.  Fluorescent ligands for the study of receptors. , 1996, Trends in pharmacological sciences.

[9]  Detecting estrogens in food and the environment , 1999, Nature Biotechnology.

[10]  Vinod P. Shah,et al.  Bioanalytical Method Validation—A Revisit with a Decade of Progress , 2000, Pharmaceutical Research.

[11]  P. Chambon,et al.  Cloning of the human estrogen receptor cDNA. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Triggle,et al.  Concepts and progress in the development and utilization of receptor‐specific fluorescent ligands , 1994, Medicinal research reviews.

[14]  D. Triggle,et al.  Selective fluorescent ligands for pharmacological receptors , 1994 .

[15]  K. Ensing,et al.  Methodological aspects of quantitative receptor assays. , 1994, Journal of pharmaceutical and biomedical analysis.

[16]  U. Schopfer,et al.  Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes. , 2002, Journal of medicinal chemistry.

[17]  K. Grandien,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .